FDA advisory panel rejects FlibanserinLast Friday drug company Boehringer Ingelheim presented evidence to the FDA's advisory panel on their drug Flibanserin. This product, designed to tackle Hypoactive Sexual Desire Disorder (HSDD) in women had already been given plenty of media coverage focusing on 'Pink Viagra', and raised concern from scientists, healthcare staff, therapists and [...]
It's five years since I started blogging. So please put on a party hat, help yourself to some nibbles, and join me for a look back over the past half decade.
PR companies are well known for using 'fake formula' to promote products, often involving academics to front them. Now it seems companies are getting students to do this job, which raises a lot of worries for universities that they may not be aware of.
FDA advisory panel rejects Flibanserin